Evidence map›Paper›PMID 35238960›Full record

Trial reportEuropean journal of clinical pharmacology2022

Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients.

Gaidaa M Dogheim, Ibtsam Khairat, Gamal A Omran, Sahar M El-Haggar, Ahmed M El Amrawy, Rehab H Werida

2 registry-linked trialsOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of clinical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04448899 phase4completednot on this map

Effects of Ivabradine on Neopterin and NT-Pro BNP in Patients With Congestive Heart Failure

TypeinterventionalSponsorDamanhour UniversityRan2020 to 2021Enrolled60ConditionsCongestive Heart FailureArmsIvabradine Oral Tablet, Blacebo plus standard treatment
NCT05881720 phase4completednot on this map

Effect of Sacubitril/Valsartan Versus Valsartan on Left Ventricular Ejection Fraction and Biomarker in Heart Failure

TypeinterventionalSponsorDamanhour UniversityRan2022 to 2023Enrolled80ConditionsHeart FailureArmsSacubitril / Valsartan Oral Tablet, Valsartan 80 mg
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Gaidaa M DogheimPharmacy Practice Department, Faculty of Pharmacy, Alexandria University, Al Mesallah Sharq, Qism Bab Sharqi, Alexandria, Alexandria Governorate, Egypt. jayda.maher@alexu.edu.eg.ORCID http://orcid.org/0000-0002-2505-0915
Ibtsam KhairatCardiology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Gamal A OmranBiochemistry Department, Faculty of Pharmacy, Damanhour University, Damanhour, 22514, Egypt.
Sahar M El-HaggarClinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Ahmed M El AmrawyCardiology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Rehab H WeridaClinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, Damanhour University, Damanhour, 22514, Egypt.ORCID http://orcid.org/0000-0002-5983-3993
Alexandria University · EGDamanhour University · EGTanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHeart rate reduction (HR) is a cornerstone in heart failure therapy as it improves patient outcomes. The aim of this study is to evaluate short-term effect of ivabradine on NT-Pro BNP and neopterin in heart failure patients and assess the association between HR and these biomarkers.

methodsSixty patients on standard heart failure therapy were randomly allocated into ivabradine group (n = 30) and non-ivabradine group (n = 30). Ivabradine 5 mg twice daily was given for 3 months. Lipid profile and kidney functions were performed and blood samples for NT-Pro BNP and neopterin were analysed at baseline and after 3 months of intervention in both groups.

resultsThere was a significant improvement in NYHA class in ivabradine group (p < 0.001). Ejection fraction was improved in ivabradine and non-ivabradine groups after intervention (p < 0.001), with a greater improvement in ivabradine group (p = 0.026). Heart rate was reduced in ivabradine group (p < 0.001) and non-ivabradine group (p < 0.001) yet greater reduction was seen in ivabradine group (p < 0.001). Serum creatinine and blood urea nitrogen were reduced in ivabradine group (Scr: p = 0.001, BUN: p = 0.001). NT-Pro BNP and neopterin levels significantly decreased in ivabradine group (NT-Pro BNP: p < 0.001, neopterin p < 0.001). Significant positive correlation was found between HR and biomarker levels after intervention (NT-Pro BNP: r = 0.475, p < 0.001, neopterin: r = 0.384, p = 0.002).

conclusionIvabradine therapy reduced levels of both biomarkers which correlated well with HR. Biomarker levels might provide a tool for assessing ivabradine effectiveness in HF. Trial registration Date: June 26, 2020. Identifier: NCT04448899. Link: Ivabradine in Patients with Congestive Heart Failure-Full Text View-ClinicalTrials.gov.

Indexed as

Heart FailureNatriuretic Peptide, BrainAnti-Arrhythmia AgentsBiomarkersChronic DiseaseDiureticsHumansIvabradineNeopterinStroke VolumeAnti-Arrhythmia AgentsBiomarkersDiureticsIvabradineNatriuretic Peptide, BrainNeopterinHeart failureIvabradineNatriuretic peptideNeopterinN-Terminal-pro BNP

Identifiers

PMID35238960
PMCPMC9107441
OpenAlexW4214868015

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.